Acadia Pharmaceuticals Inc.
Here’s whether Acadia Pharmaceuticals Inc. (ACAD) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 62 — healthy momentum range; strong 1-year return of +52.2%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-3.38% over 10 days); 3-month momentum negative (-14.7%). Currently 21.8% off its 52-week high. Score: -3/7.
ACAD is trading below its 200-day MA ($23.72) — a key warning sign the longer-term trend is under pressure. An RSI of 62.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +52.2% compares to +35.1% for SPY (beat the market by 17.1%). The current 21.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.